Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; Chang Gung University College of Medicine, Kaohsiung, Taiwan.
J Microbiol Immunol Infect. 2018 Oct;51(5):621-628. doi: 10.1016/j.jmii.2016.08.022. Epub 2017 Jun 23.
BACKGROUND/PURPOSE: A substantial number of carbapenem-resistant Gram-negative bacilli (CR GNB) have been identified among the etiologic multidrug-resistant GNB in healthcare-associated infections. For achieving a better therapeutic outcome by minimizing inappropriate empirical antibiotic treatment before blood culture and susceptibility testing results are available, it is very important to identify patients who are at risk for the development of CR GNB bacteremia.
Retrospective analysis of propensity-score matched (PSM) adult patients with CR GNB bacteremia (PSM-group 1 [n = 95]) and those with non-CR GNB bacteremia (PSM-group 2 [n = 190]).
PSM-group 1 was found to a significantly longer length of hospital stay (27 vs. 18 days; p < 0.001) after emerging GNB bacteremia and a higher 30-day all-cause mortality rate (27.4% vs. 5.8%; p < 0.001), when compared with PSM-2 group. Independent risk factors for the acquisition of CR GNB bacteremia were previous exposure to an antipseudomonal penicillin (odds ratio [OR] = 3.58; 95% confidence interval [CI] = 1.30-9.90), an antipseudomonal cephalosporin (OR = 3.49; 95% CI = 1.09-11.24), and a carbapenem (OR = 3.60; 95% CI = 1.37-9.47), and longer length of hospital stay before the development of GNB bacteremia (OR = 1.03; 95% CI = 1.01-1.05).
Risk factors for acquisition of CR GNB bacteremia identified in this study each may serve as a reminder alerting clinicians to hospitalized patients at risk for CR GNB bacteremia requiring appropriate antibiotic coverage, and in these circumstances, combined antibiotics may be used until antimicrobial de-escalation/adjustment is clearly indicated by the subsequently identified pathogenic GNB and its susceptibility profile.
背景/目的:在与医疗保健相关的感染中,已发现相当数量的耐碳青霉烯类革兰氏阴性菌(CR GNB)是引起多重耐药性革兰氏阴性菌的病因。为了通过在获得血培养和药敏试验结果之前尽量减少不适当的经验性抗生素治疗,从而实现更好的治疗效果,确定发生 CR GNB 菌血症的高危患者非常重要。
回顾性分析了耐碳青霉烯类革兰氏阴性菌菌血症患者(匹配后病例组 1 [n=95])和非耐碳青霉烯类革兰氏阴性菌菌血症患者(匹配后病例组 2 [n=190])的倾向性评分匹配(PSM)成人患者。
与匹配后病例组 2 相比,出现革兰氏阴性菌菌血症后,匹配后病例组 1 的住院时间明显延长(27 天 vs. 18 天;p<0.001),30 天全因死亡率也更高(27.4% vs. 5.8%;p<0.001)。获得耐碳青霉烯类革兰氏阴性菌菌血症的独立危险因素包括先前使用抗假单胞菌青霉素(比值比 [OR] = 3.58;95%置信区间 [CI] = 1.30-9.90)、抗假单胞菌头孢菌素(OR = 3.49;95% CI = 1.09-11.24)和碳青霉烯类药物(OR = 3.60;95% CI = 1.37-9.47),以及在发生革兰氏阴性菌菌血症之前的住院时间更长(OR = 1.03;95% CI = 1.01-1.05)。
本研究确定的获得耐碳青霉烯类革兰氏阴性菌菌血症的危险因素可能会提醒临床医生注意有发生耐碳青霉烯类革兰氏阴性菌菌血症风险的住院患者,需要适当覆盖抗生素治疗,在这些情况下,在随后确定的致病性革兰氏阴性菌及其药敏谱明确提示需要减少或调整抗生素之前,可以联合使用抗生素。